Abstract
Rho GTPase controls multiple signal-transduction pathways involving the actin cytoskeleton and the microtubule cytoskeleton in processes such as the cell cycle, morphogenesis, and cell migration. The activity of Rho GTPases, such as Rac1, Cdc42, and RhoA, is regulated by GTPase-activating proteins (GAPs), guanine nucleotide exchange factors (GEFs), and guanine nucleotide dissociation inhibitor (GDI). The GEFs activate Rho GTPases through exchange of GDP for GTP. A group of the GEF family, CDM-GEF, containing the Dock180 Homology Region 2 (DHR2) domain is subdivided into four groups based on amino acid sequences. One of these subgroups, DOCK-A, includes DOCK1, DOCK2, and DOCK5, and activates Rac1 Rho GTPase. Mouse Dock5 (mDock5) is structurally similar to DOCK1 and composed of 1868 amino acids containing Src homology 3 (SH3), DHR1, DHR2, and a proline-rich (PR) motif. We generated an mDock5-specific antibody, which detected denatured and nascent forms of mDock5. We determined tissue-specific expression patterns and subcellular localization of mDock5 using this antibody. This antibody provides a way to delineate the biological functions of mDock5 in vivo.
Keywords: DOCK family, GEF, mDock5 (PPK) polyclonal antibody
Protein & Peptide Letters
Title: Characterization of an mDock5-Specific Antibody and Tissue-Specific Expression and Subcellular Localization of mDock5
Volume: 17 Issue: 4
Author(s): Eunmin Kim, Jong-Bok Yoon and SungJoo Kim Yoon
Affiliation:
Keywords: DOCK family, GEF, mDock5 (PPK) polyclonal antibody
Abstract: Rho GTPase controls multiple signal-transduction pathways involving the actin cytoskeleton and the microtubule cytoskeleton in processes such as the cell cycle, morphogenesis, and cell migration. The activity of Rho GTPases, such as Rac1, Cdc42, and RhoA, is regulated by GTPase-activating proteins (GAPs), guanine nucleotide exchange factors (GEFs), and guanine nucleotide dissociation inhibitor (GDI). The GEFs activate Rho GTPases through exchange of GDP for GTP. A group of the GEF family, CDM-GEF, containing the Dock180 Homology Region 2 (DHR2) domain is subdivided into four groups based on amino acid sequences. One of these subgroups, DOCK-A, includes DOCK1, DOCK2, and DOCK5, and activates Rac1 Rho GTPase. Mouse Dock5 (mDock5) is structurally similar to DOCK1 and composed of 1868 amino acids containing Src homology 3 (SH3), DHR1, DHR2, and a proline-rich (PR) motif. We generated an mDock5-specific antibody, which detected denatured and nascent forms of mDock5. We determined tissue-specific expression patterns and subcellular localization of mDock5 using this antibody. This antibody provides a way to delineate the biological functions of mDock5 in vivo.
Export Options
About this article
Cite this article as:
Kim Eunmin, Yoon Jong-Bok and Yoon Kim SungJoo, Characterization of an mDock5-Specific Antibody and Tissue-Specific Expression and Subcellular Localization of mDock5, Protein & Peptide Letters 2010; 17 (4) . https://dx.doi.org/10.2174/092986610790963681
DOI https://dx.doi.org/10.2174/092986610790963681 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Mechanisms and Aberrant Gene Expression during the Development of Gastric Intestinal Metaplasia and Adenocarcinoma
Current Genomics Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics
Current Medicinal Chemistry Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets Cornea: Window to Ocular Immunology
Current Immunology Reviews (Discontinued) Drug Repositioning for the Treatment of Hematologic Disease: Limits, Challenges and Future Perspectives
Current Medicinal Chemistry Expression of Defensins in Gingiva and Their Role in Periodontal Health and Disease
Current Pharmaceutical Design Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry A Novel Technology for Hematopoietic Stem Cell Expansion Using Combination of Nanofiber and Growth Factors
Recent Patents on Nanotechnology Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Molecular Targets of FoxP3+ Regulatory T Cells
Mini-Reviews in Medicinal Chemistry Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design Anticancer Mechanisms of Bioactive Peptides
Protein & Peptide Letters Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects
Anti-Cancer Agents in Medicinal Chemistry Studies on the Biotransformations and Biodistributions of Metal-Containing Drugs Using X-Ray Absorption Spectroscopy
Current Topics in Medicinal Chemistry Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Anti-Cancer Agents in Medicinal Chemistry